{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:30:35Z","timestamp":1760239835465,"version":"build-2065373602"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.hoc.2020.09.004","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T09:21:37Z","timestamp":1603704097000},"page":"85-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Extracutaneous Melanoma"],"prefix":"10.1016","volume":"35","author":[{"given":"Richard","family":"Carvajal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan","family":"Maniar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.hoc.2020.09.004_bib1","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/cncr.20866","article-title":"Incidence of noncutaneous melanomas in the U.S","volume":"103","author":"McLaughlin","year":"2005","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2020.09.004_bib2","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","article-title":"The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2020.09.004_bib3","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1097\/SAP.0000000000000731","article-title":"Clinical Patterns of Melanoma in Asians: 11-Year Experience in a Tertiary Referral Center","volume":"77","author":"Chan","year":"2016","journal-title":"Ann Plast Surg"},{"issue":"2","key":"10.1016\/j.hoc.2020.09.004_bib4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaad.2016.08.007","article-title":"Mucosal melanomas in the racially diverse population of California","volume":"76","author":"Altieri","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2020.09.004_bib5","first-page":"116","article-title":"An updated review of mucosal melanoma: Survival meta-analysis","volume":"11","author":"Hahn","year":"2019","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.09.004_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.6004\/jnccn.2012.0034","article-title":"Mucosal melanoma: a clinically and biologically unique disease entity","volume":"10","author":"Carvajal","year":"2012","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.hoc.2020.09.004_bib7","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jaad.2018.09.054","article-title":"Predictors of mucosal melanoma survival in a population-based setting","volume":"81","author":"Altieri","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.hoc.2020.09.004_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/path.4204","article-title":"Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma","volume":"230","author":"Furney","year":"2013","journal-title":"J\u00a0Pathol"},{"issue":"7653","key":"10.1016\/j.hoc.2020.09.004_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.hoc.2020.09.004_bib10","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","article-title":"Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets","volume":"10","author":"Newell","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2020.09.004_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semcancer.2019.09.013","article-title":"The mutational landscape of mucosal melanoma","volume":"61","author":"Nassar","year":"2020","journal-title":"Semin Cancer Biol"},{"issue":"22","key":"10.1016\/j.hoc.2020.09.004_bib12","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.004_bib13","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/1078-0432.CCR-15-1110","article-title":"Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors","volume":"22","author":"Kong","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2020.09.004_bib14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2016.06.019","article-title":"GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis","volume":"65","author":"Sheng","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2020.09.004_bib15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12967-019-1987-z","article-title":"Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy","volume":"17","author":"Xu","year":"2019","journal-title":"J\u00a0Transl Med"},{"issue":"9","key":"10.1016\/j.hoc.2020.09.004_bib16","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/labinvest.2017.64","article-title":"Melanoma subtypes demonstrate distinct PD-L1 expression profiles","volume":"97","author":"Kaunitz","year":"2017","journal-title":"Lab Invest"},{"issue":"12","key":"10.1016\/j.hoc.2020.09.004_bib17","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/archoto.2009.173","article-title":"Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results","volume":"135","author":"Hanna","year":"2009","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.004_bib18","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/SLA.0000000000000862","article-title":"Abdominoperineal resection provides better local control but equivalent overall survival to local excision of anorectal malignant melanoma: a systematic review","volume":"261","author":"Matsuda","year":"2015","journal-title":"Ann Surg"},{"issue":"16","key":"10.1016\/j.hoc.2020.09.004_bib19","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1158\/1078-0432.CCR-13-0739","article-title":"Phase II randomized trial comparing high-dose IFN-\u03b12b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma","volume":"19","author":"Lian","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2020.09.004_bib20","doi-asserted-by":"crossref","first-page":"9589","DOI":"10.1200\/JCO.2018.36.15_suppl.9589","article-title":"Phase \u2162 randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma","volume":"36","author":"Lian","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2020.09.004_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/CMR.0000000000000306","article-title":"Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma","volume":"27","author":"Shoushtari","year":"2017","journal-title":"Melanoma Res"},{"issue":"5","key":"10.1016\/j.hoc.2020.09.004_bib22","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.bjc.6604482","article-title":"Phase II trial of imatinib mesylate in patients with metastatic melanoma","volume":"99","author":"Kim","year":"2008","journal-title":"Br J Cancer"},{"issue":"21","key":"10.1016\/j.hoc.2020.09.004_bib23","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.hoc.2020.09.004_bib24","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.09.004_bib25","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1634\/theoncologist.2012-0464","article-title":"Ipilimumab for patients with advanced mucosal melanoma","volume":"18","author":"Postow","year":"2013","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.hoc.2020.09.004_bib26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/mmt-2017-0014","article-title":"Immune checkpoint inhibitors in the treatment of advanced mucosal melanoma","volume":"4","author":"Kuo","year":"2017","journal-title":"Melanoma Manag"},{"issue":"21","key":"10.1016\/j.hoc.2020.09.004_bib27","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.30259","article-title":"The efficacy of anti-PD-1 agents in acral and mucosal melanoma","volume":"122","author":"Shoushtari","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2020.09.004_bib28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis","volume":"35","author":"D'Angelo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.09.004_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000480640","article-title":"Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1973-2013)","volume":"4","author":"Aronow","year":"2018","journal-title":"Ocul Oncol Pathol"},{"issue":"12","key":"10.1016\/j.hoc.2020.09.004_bib30","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/jnci\/djy171","article-title":"Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide","volume":"110","author":"Walpole","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.hoc.2020.09.004_bib31","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.ophtha.2005.04.020","article-title":"Intermittent and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis","volume":"112","author":"Shah","year":"2005","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.004_bib32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.survophthal.2004.04.009","article-title":"Sunlight exposure and pathogenesis of uveal melanoma","volume":"49","author":"Singh","year":"2004","journal-title":"Surv Ophthalmol"},{"issue":"11","key":"10.1016\/j.hoc.2020.09.004_bib33","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.hoc.2020.09.004_bib34","doi-asserted-by":"crossref","first-page":"e0116371","DOI":"10.1371\/journal.pone.0116371","article-title":"Digital PCR validates 8q dosage as prognostic tool in uveal melanoma","volume":"10","author":"Versluis","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.hoc.2020.09.004_bib35","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41588-019-0440-9","article-title":"The genetic evolution of metastatic uveal melanoma","volume":"51","author":"Shain","year":"2019","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.hoc.2020.09.004_bib36","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.hoc.2020.09.004_bib37","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/CMR.0000000000000121","article-title":"GNAQ and GNA11 mutations in uveal melanoma","volume":"24","author":"Shoushtari","year":"2014","journal-title":"Melanoma Res"},{"issue":"6009","key":"10.1016\/j.hoc.2020.09.004_bib38","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.hoc.2020.09.004_bib39","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ng.2674","article-title":"Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3","volume":"45","author":"Martin","year":"2013","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.hoc.2020.09.004_bib40","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.1167\/iovs.11-9280","article-title":"Different Subsets of Tumor-Infiltrating Lymphocytes Correlate with Macrophage Influx and Monosomy 3 in Uveal Melanoma","volume":"53","author":"Bronkhorst","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"10.1016\/j.hoc.2020.09.004_bib41","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1167\/iovs.12-10123","article-title":"Cytokines and Chemokines in the Vitreous Fluid of Eyes with Uveal Melanoma","volume":"53","author":"Nagarkatti-Gude","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.hoc.2020.09.004_bib42","first-page":"223","article-title":"Infiltrative T regulatory cells in enucleated uveal melanomas","volume":"107","author":"Lagouros","year":"2009","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"6","key":"10.1016\/j.hoc.2020.09.004_bib43","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ajo.2004.07.006","article-title":"The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24","volume":"138","author":"Hawkins","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.hoc.2020.09.004_bib44","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0161-6420(89)32648-0","article-title":"Uveal melanoma radiation. 125I brachytherapy versus helium ion irradiation","volume":"96","author":"Char","year":"1989","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.hoc.2020.09.004_bib45","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13014-018-1088-9","article-title":"Linear accelerator-based stereotactic fractionated photon radiotherapy as an eye-conserving treatment for uveal melanoma","volume":"13","author":"Akbaba","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.hoc.2020.09.004_bib46","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2016.09.009","article-title":"Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome","volume":"68","author":"Marinkovic","year":"2016","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2020.09.004_bib47","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.ophtha.2009.04.044","article-title":"Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis","volume":"116","author":"Lane","year":"2009","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.004_bib48","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/bjophthalmol-2019-314461","article-title":"A\u00a0prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes","volume":"104","author":"Binkley","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.hoc.2020.09.004_bib49","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ophtha.2017.08.017","article-title":"Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls","volume":"125","author":"Valsecchi","year":"2018","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.hoc.2020.09.004_bib50","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/cancers11020152","article-title":"Adjuvant Ipilimumab in High-Risk Uveal Melanoma","volume":"11","author":"Fountain","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.hoc.2020.09.004_bib51","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.004_bib52","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","article-title":"Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases","volume":"23","author":"Hughes","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.09.004_bib53","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/CMR.0b013e3283610586","article-title":"Treatment of metastatic uveal melanoma with intravenous fotemustine","volume":"23","author":"Spagnolo","year":"2013","journal-title":"Melanoma Res"},{"issue":"12","key":"10.1016\/j.hoc.2020.09.004_bib54","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/annonc\/mdl309","article-title":"A\u00a0randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma","volume":"17","author":"Schmittel","year":"2006","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2020.09.004_bib55","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.1200\/jco.2014.32.15_suppl.9033","article-title":"Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial","volume":"32","author":"Piulats Rodriguez","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.09.004_bib56","doi-asserted-by":"crossref","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-study of ipilimumab in pretreated and treatment-na\u00efve patients with metastatic uveal melanoma","volume":"10","author":"Zimmer","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.hoc.2020.09.004_bib57","doi-asserted-by":"crossref","first-page":"e1143997","DOI":"10.1080\/2162402X.2016.1143997","article-title":"Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma","volume":"5","author":"Karydis","year":"2016","journal-title":"Oncoimmunology"},{"issue":"21","key":"10.1016\/j.hoc.2020.09.004_bib58","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/cncr.30258","article-title":"Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies","volume":"122","author":"Algazi","year":"2016","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.hoc.2020.09.004_bib59","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2014.6096","article-title":"Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial","volume":"311","author":"Carvajal","year":"2014","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.hoc.2020.09.004_bib60","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.21873\/anticanres.12665","article-title":"The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence","volume":"38","author":"Moschos","year":"2018","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.004_bib61","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/annonc\/mdw694","article-title":"The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients","volume":"28","author":"Lian","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.09.004_bib62","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaad.2006.06.017","article-title":"Primary mucosal melanoma","volume":"56","author":"Patrick","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.hoc.2020.09.004_bib63","first-page":"92","article-title":"Outcomes for patients with metastatic uveal melanoma (MUM) treated with ipilimumab and nivolumab (cIN): a multi-center, retrospective study. SMR Congress 2018 Abstracts","volume":"32","author":"Najjar","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"10.1016\/j.hoc.2020.09.004_bib64","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s40425-019-0800-0","article-title":"Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study","volume":"7","author":"Heppt","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2020.09.004_bib65","doi-asserted-by":"crossref","first-page":"9522","DOI":"10.1200\/JCO.2019.37.15_suppl.9522","article-title":"Phase II study of ipilimumab and nivolumab (ipi\/nivo) in metastatic uveal melanoma (UM)","volume":"37","author":"Pelster","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl_8","key":"10.1016\/j.hoc.2020.09.004_bib66","first-page":"viii4442","article-title":"Phase II multicenter, single arm, open label study of Nivolumab in combination with Ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402)","volume":"29","author":"Piulats Rodriguez","year":"2018","journal-title":"Annals of Oncology"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820301180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820301180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:16:23Z","timestamp":1760184983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820301180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0889858820301180"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.09.004","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extracutaneous Melanoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}